Overview

Olorinab in IBS-C and IBS-D

Status:
Terminated

Trial end date:
2021-04-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).

Phase:

Phase 2

Details

Lead Sponsor:

Arena Pharmaceuticals